Phathom Pharmaceuticals (PHAT) Q4 2025 earnings summary

Executive summary

• Achieved strong Q4 and full-year 2025 results, with net revenues of $57.6 million in Q4 and $175.1 million for FY 2025, marking a 217% year-over-year increase.

• Revenue growth driven by GI-focused strategy, sales force realignment, and increased sales force productivity.

• Enhanced capital structure through $130 million equity offering and term loan modification, reducing interest expense, extending maturity, and improving financial flexibility.

• Positioned for operating profitability in Q3 2026 and cash flow positivity in 2027.

Financial highlights

• Full-year 2025 net revenue reached $175.1 million, up 217% year-over-year; Q4 revenue was $57.6 million, up 16% sequentially.

• Gross margin remained strong at approximately 87% for Q4 and full year.

• Q4 cash operating expenses (excluding stock-based compensation) were $50.3 million, nearly 50% lower than prior quarters.

• Q4 net cash usage was $5.2 million, a 64% improvement from Q3.

• Cash and cash equivalents at year-end 2025: $130 million.

Outlook and guidance

• 2026 net revenue guidance: $320 million–$345 million, including an accounting classification change.

• Gross margin expected at ~80% for 2026.

• Cash/non-GAAP operating expenses (excluding stock-based compensation) projected at $235 million–$255 million.

• Operating profitability targeted by Q3 and for full year 2026; cash flow positivity in 2027.

• Revenue expected to be 40% in H1 and 60% in H2, with Q1 as the softest quarter due to seasonality.